Jordi Rodón

Research interests

Publications

• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02103-8

• The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

  Nature Cancer · 2022 · https://doi.org/10.1038/s43018-022-00332-x

• 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

  Nature Communications · 2021 · 10.1038/s41467-021-25894-9

• A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

  Radiology · 2021 · https://doi.org/10.1148/radiol.2021200928

• Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

  British Journal of Cancer · 2021 · https://doi.org/10.1038/s41416-021-01389-8

• 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

  Nature Communications · 2021 · 10.1038/s41467-021-25894-9

• Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-19-2226

• Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

  Cancer Cell · 2019 · 10.1016/j.ccell.2019.09.001

• Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

  Nature Medicine · 2019 · https://doi.org/10.1038/s41591-019-0424-4

• Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

  Cancer Cell · 2019 · 10.1016/j.ccell.2019.09.001

• New clinical trial designs in the era of precision medicine

  Molecular Oncology · 2019 · https://doi.org/10.1002/1878-0261.12465

• Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-18-2275

• Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.72.7107

• Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  Genome Medicine · 2018 · https://doi.org/10.1186/s13073-018-0531-8

• BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.9990

• Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

  JAMA Oncology · 2018 · 10.1001/jamaoncol.2018.4475

• HER kinase inhibition in patients with HER2- and HER3-mutant cancers

  Nature · 2018 · https://doi.org/10.1038/nature25475

• Actively personalized vaccination trial for newly diagnosed glioblastoma

  Nature · 2018 · https://doi.org/10.1038/s41586-018-0810-y

• Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

  JAMA Oncology · 2018 · 10.1001/jamaoncol.2018.4475

• A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

  Neuro-Oncology · 2016 · https://doi.org/10.1093/neuonc/now009

• Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.60.7341

• Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

  Nature Communications · 2015 · https://doi.org/10.1038/ncomms9839

• AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

  Cancer Cell · 2015 · 10.1016/j.ccell.2015.03.010

• PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

  Science Translational Medicine · 2015 · https://doi.org/10.1126/scitranslmed.aaa4442

• AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

  Cancer Cell · 2015 · 10.1016/j.ccell.2015.03.010

• First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

  Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-14-1380

• First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

  Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-14-1380

• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  Molecular Cancer Therapeutics · 2014 · https://doi.org/10.1158/1535-7163.mct-13-0639

• Development of PI3K inhibitors: lessons learned from early clinical trials

  Nature Reviews Clinical Oncology · 2013 · https://doi.org/10.1038/nrclinonc.2013.10

• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt419

• mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer

  Science Translational Medicine · 2013 · https://doi.org/10.1126/scitranslmed.3005747

• PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

  Cancer Discovery · 2012 · https://doi.org/10.1158/2159-8290.cd-11-0348

• Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2011.36.1360

• TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma

  Cancer Cell · 2010 · https://doi.org/10.1016/j.ccr.2010.10.023

• Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.6745

• Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.6745

Current projects

No projects listed.